Your browser doesn't support javascript.
loading
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.
Perez, Cristina; Botta, Cirino; Zabaleta, Aintzane; Puig, Noemi; Cedena, Maria-Teresa; Goicoechea, Ibai; Alameda, Daniel; San José-Eneriz, Edurne; Merino, Juana; Rodríguez-Otero, Paula; Maia, Catarina; Alignani, Diego; Maiso, Patricia; Manrique, Irene; Lara-Astiaso, David; Vilas-Zornoza, Amaia; Sarvide, Sarai; Riillo, Caterina; Rossi, Marco; Rosiñol, Laura; Oriol, Albert; Blanchard, María-Jesús; Rios, Rafael; Sureda, Anna; Martin, Jesus; Martinez, Rafael; Bargay, Joan; de la Rubia, Javier; Hernandez, Miguel-Teodoro; Martinez-Lopez, Joaquin; Orfao, Alberto; Agirre, Xabier; Prosper, Felipe; Mateos, Maria-Victoria; Lahuerta, Juan-José; Blade, Joan; San-Miguel, Jesús F; Paiva, Bruno.
Afiliación
  • Perez C; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Botta C; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Zabaleta A; Department of Oncohematology, "Annunziata" Hospital, Cosenza, Italy.
  • Puig N; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Cedena MT; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233, Salamanca, Spain.
  • Goicoechea I; Hospital 12 de Octubre, CIBER-ONC number CB16/12/00369, Madrid, Spain.
  • Alameda D; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • San José-Eneriz E; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Merino J; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Rodríguez-Otero P; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Maia C; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Alignani D; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Maiso P; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Manrique I; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Lara-Astiaso D; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Vilas-Zornoza A; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Sarvide S; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Riillo C; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Rossi M; Department of Clinical and Experimental Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
  • Rosiñol L; Department of Clinical and Experimental Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
  • Oriol A; Hospital Clínic IDIBAPS, Barcelona, Spain.
  • Blanchard MJ; Institut Català d'Oncologia i Institut Josep Carreras, Badalona, Spain.
  • Rios R; Hospital Ramón y Cajal, Madrid, Spain.
  • Sureda A; Hospital Virgen de las Nieves, Granada, Spain.
  • Martin J; Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain.
  • Martinez R; Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC CB16/12/00480), Seville, Spain.
  • Bargay J; Hospital Clínico San Carlos, Madrid, Spain.
  • de la Rubia J; Hospital Son Llatzer, Palma de Mallorca, Spain.
  • Hernandez MT; Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Martinez-Lopez J; School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain.
  • Orfao A; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
  • Agirre X; Hospital 12 de Octubre, CIBER-ONC number CB16/12/00369, Madrid, Spain.
  • Prosper F; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233, Salamanca, Spain.
  • Mateos MV; Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), CIBER-ONC number CB16/12/00400, Salamanca, Spain.
  • Lahuerta JJ; Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain; and.
  • Blade J; Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, Spain.
  • San-Miguel JF; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
  • Paiva B; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.
Blood ; 136(2): 199-209, 2020 07 09.
Article en En | MEDLINE | ID: mdl-32325491
ABSTRACT
Granulocytic myeloid-derived suppressor cells (G-MDSCs) promote tumor growth and immunosuppression in multiple myeloma (MM). However, their phenotype is not well established for accurate monitoring or clinical translation. We aimed to provide the phenotypic profile of G-MDSCs based on their prognostic significance in MM, immunosuppressive potential, and molecular program. The preestablished phenotype of G-MDSCs was evaluated in bone marrow samples from controls and MM patients using multidimensional flow cytometry; surprisingly, we found that CD11b+CD14-CD15+CD33+HLADR- cells overlapped with common eosinophils and neutrophils, which were not expanded in MM patients. Therefore, we relied on automated clustering to unbiasedly identify all granulocytic subsets in the tumor microenvironment basophils, eosinophils, and immature, intermediate, and mature neutrophils. In a series of 267 newly diagnosed MM patients (GEM2012MENOS65 trial), only the frequency of mature neutrophils at diagnosis was significantly associated with patient outcome, and a high mature neutrophil/T-cell ratio resulted in inferior progression-free survival (P < .001). Upon fluorescence-activated cell sorting of each neutrophil subset, T-cell proliferation decreased in the presence of mature neutrophils (0.5-fold; P = .016), and the cytotoxic potential of T cells engaged by a BCMA×CD3-bispecific antibody increased notably with the depletion of mature neutrophils (fourfold; P = .0007). Most interestingly, RNA sequencing of the 3 subsets revealed that G-MDSC-related genes were specifically upregulated in mature neutrophils from MM patients vs controls because of differential chromatin accessibility. Taken together, our results establish a correlation between the clinical significance, immunosuppressive potential, and transcriptional network of well-defined neutrophil subsets, providing for the first time a set of optimal markers (CD11b/CD13/CD16) for accurate monitoring of G-MDSCs in MM.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antígenos CD / Células Supresoras de Origen Mieloide / Mieloma Múltiple / Proteínas de Neoplasias Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2020 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antígenos CD / Células Supresoras de Origen Mieloide / Mieloma Múltiple / Proteínas de Neoplasias Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2020 Tipo del documento: Article País de afiliación: España